Active Pharmaceutical Ingredient Market is Anticipated to Show the Robust Growth During 2015 - 2023

Active Pharmaceutical Ingredient (API) refers to a substance or substance combination used in manufacturing a drug product. The active pharmaceutical ingredient market has been categorized by manufacturing process, API type, drug type, therapeutic area and geography. Manufacturing processes in the global API market include captive and contract manufacturing. The captive API manufacturing segment comprises the active pharmaceutical ingredients produced for internal consumption of a pharmaceutical company. Captive manufacturing accounted for the highest market share in 2014, however the share of this market segment is expected to witness a decline due high degree of competition from contract manufacturing and reduced profitability and thus increased preference for outsourcing API production over captive production. Outsourcing production helps pharmaceutical companies focus on their core business of developing new drug products. Contract manufacturing is being preferred because of its advantage in terms of capital and labor costs, access to advanced manufacturing technologies, and benefits from the global distribution network.

This 115 page report gives readers a comprehensive overview of the Active Pharmaceutical Ingredient Market. Browse to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/active-pharmaceutical-ingredients.html

The global active pharmaceutical market is segmented into API types: synthetic chemical API and biological API. The synthetic chemical API segment held the largest share of more than 70% of active pharmaceutical market in 2014. This market segment has evolved in the past few years due to innovations in the methods of synthesizing chemical APIs, which improves their stability and potency. The large volume of the demand is an important reason for the larger share of synthetic chemical API segment. On the other hand, the biological API market segment is expected to have the highest growth rate of 8.1% during the forecast period of 2015-2023. Large pharmaceutical companies are scaling down their small molecule manufacturing facilities to focus on biologic drugs, thereby presenting greater opportunities for contract manufacturing companies. The overall cost of drug development program for biologics is less as compared to chemical APIs, primarily because of high success rates in the pipeline phase. This factor has attracted higher investments in the biologics and biosimilars market.

Drug types in the global API market include branded prescription drug, generic prescription drug and OTC drugs. The branded API segment accounted for the largest share of 76% in the global API market in 2014. The factors driving the branded prescription drugs include government initiatives that has lowered the copayment on generics while raising it on the branded drugs. The increasing demand for biological drugs and supportive policies of the European Union toward biosimilars is also one of the major driving factors to boost branded API market. Moreover, the generic prescription drugs segment is expected to grow at the highest rate of 7.3% during the forecast period. With the rising cost of healthcare, governments and payers are pushing for the increasing generics consumption over branded drugs, thus driving growth of the generic APIs market. Over-the-counter (drugs) are considered sufficiently safe and effective for use without prescriptions from health care professionals and hence would continue to grow at a steady rate during the forecast period.

Based on the therapeutic area, the global API market is segmented into various disorders such as cardiovascular, metabolic, disorders, oncology, musculoskeletal, non-steroidal anti-inflammatory drugs (NSAIDs), and others. The cardiovascular disorder segment held the largest share of global active pharmaceutical ingredient market during the forecast period. Cardiovascular, metabolic, and neurological disorders held a combined market share of over 50% in 2014 due to the rising geriatric population, increasing prevalence of cardiovascular diseases, diabetes and neurological disease globally. Whereas, the oncology segment is expected to grow at the highest rate of 8.2% during the forecast period owing to the rising prevalence of cancer. The significant growth observed in oncology API has helped companies to prefer specialized manufacturing plants for oncology drugs. The musculoskeletal disorders, NSAIDs and other therapeutics area is anticipated to grow at a steady rate during the forecast period of 2015 to 2023.

Request a sample of this report to know what opportunities will emerge in the rapidly evolving

Active Pharmaceutical Ingredient Market during 2015 - 2023: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1690

Geographically, North America dominated the active pharmaceutical ingredient market in 2014 with a share of 35.1% owing to factors such as higher consumption of API due to the presence of major pharmaceutical companies in this region. Biologics have become one of the top-selling drugs in North America. Thus, the expected market entry of biosimilars with flexible regulatory process would further boost the API market in North America. Japan, China, India and South Korea, the leading pharmaceutical hubs in Asia are majorly responsible for almost 30% of the total market share placing the region at the second position in the world. Major factors driving the API markets in China and India are the availability of low cost production facilities and labor cost. Other factors driving the market in the region include the tax incentives, rising government expenditure on health care and government plans to restructure the fragmented industry. Europe accounted for a market share of 21.6% in 2014. The governments of various countries in Europe have started supporting the manufacture of generic drugs post the financial crisis. Patent expirations of major blockbuster drugs in Europe would fuel the growth of the API market in the near future. Demand for generic drugs is increasing not only in developed countries, but also in developing and underdeveloped countries in South America and Africa. Brazil and South Africa are the important centers of pharmaceutical manufacturing in this regional segment. Factors boosting the growth of the market in developing regions are cost-efficient manufacturing, large number of patients, rising demand for generic drugs, and improvement in the healthcare infrastructure.

Teva Pharmaceutical Industries Ltd dominated active pharmaceutical ingredients market in 2014. Major factors attributed to its dominance are broad product portfolio and high market penetration. Zhejiang Medicine Co., Ltd. and Zhejiang NHU Co., Ltd secured the second market position in 2015. North China Pharmaceutical Group Corp. (NCPC) and Northeast Pharmaceutical Group Co., Ltd. held the third position in 2015. Other players in the active pharmaceutical ingredients market include Dr.Reddy's Laboratories Limited, Sandoz (Novartis AG), Aurobindo Pharma Limited, Zhejiang Hisun Pharmaceutical Co., Ltd. and Zhejiang Huahai Pharmaceuticals Co., Ltd. and others.

Autoimmune Disease Diagnostics Market Detailed Analysis of Market Structure from 2015 to 2023

Despite its vendor landscape being highly consolidated, intense rivalry prevails among key players in the global autoimmune disease diagnostics market. According to Transparency Market Research (TMR), the top four companies held over 50% of the global autoimmune disease diagnostics market in 2014. Among the leading enterprises, F. Hoffmann-La Roche Ltd. held the dominant share of over 17% in the market in the same year.

In response to the increasing demand for effective and advanced autoimmune diseases diagnosis, TMR expects the competition among rivals to surge further. Furthermore, the market demonstrates considerable scope for new entrants. The rising demand for novel and improved autoimmune diagnostics will pave the way for the entry of new players in the market. Contrary to this, competitive pricing, rising R&D investments, and shortening product lifecycles may restrict the entry of new players.

This 80 page report gives readers a comprehensive overview of the autoimmune disease diagnostics market. Browse to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/autoimmune-disease-diagnostics-market.html

Increased Prevalence of Autoimmune Diseases a High-impact Driver

Autoimmune diseases affect millions around the world, which makes precise diagnosis extremely important. As per a lead TMR analyst, “The globally increasing incidence of autoimmune diseases is bolstering the demand for autoimmune disease diagnostics globally.”

Governments across both developed and developing nations are exploring efficient diagnosis and therapeutic options to prevent the spread of chronic ailments. This, combined with the rising healthcare spending across emerging nations, will augur well for the autoimmune disease diagnostics market in the forthcoming years. As per the TMR analyst, “The latest technological advancements witnessed in the healthcare sector will further set the tone for the market’s expansion.”

People around the world have become more aware about the prevalence of various autoimmune diseases. This not only encourages them to adopt preventive measures, but creates demand for autoimmune disease diagnostics in case of the occurrence of the disease. This increasing awareness has led to the rising demand for autoimmune diseases diagnostics globally.

Competitive Pricing Strategies by Players Could Hamper Profit Margins

Due to the prevailing competition and threat from local enterprises, the leading market players are compelled to maintain competitive pricing. This could have an adverse impact on the market’s overall growth prospects as the rising competition will slash prices of products. The market is also threatened by the lack of skilled professionals. The unavailability of trained professionals and inadequate automation create operational challenges in clinical laboratories. This could hamper the market’s trajectory in the forthcoming years.

Request a sample of this report to know what opportunities will emerge in the rapidly evolving autoimmune disease diagnostics market during 2015 - 2023: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=5351

Companies Looking to Capitalize on Opportunities in Asia Pacific to Expand their Footprint

The future of the autoimmune disease diagnostics market looks promising with multinational companies capitalizing on the opportunities mushrooming in the emerging economies of Asia. Besides this, the companies are also focusing on automating laboratories and replacing conventional technologies. The advent of novel technologies holds lucrative opportunities for the market’s future.

By disease type, rheumatoid arthritis accounted for the largest share in the market in 2014. The segment is expected to remain the dominant segment surging at 4.2% CAGR between 2015 and 2023. Regionally, North America led the global autoimmune disease diagnostics market in 2014 with a share of 39%.

As per TMR, the global autoimmune disease diagnostics market stood at US$12.3 bn in 2014. Rising at a CAGR of 3.8%, the market is expected to reach US$17.06 bn by the end of 2023.

Tissue Engineered Skin Substitutes Market Set to Expand by 2023

The global market for tissue engineered skin substitutes is mostly consolidated as four companies currently maintain a strong hold over revenue shares in market value. The top three players in 2014 were Acelity, Smith & Nephew, and Molnlycke. Their collective share in market value in 2014 was 51.4%. Most commonly, the key providers of tissue engineered skin substitutes offer a wide product profile, invest heavily in research and development to stay ahead of the pack, and possess strong marketing processes and distribution networks.

As a result, although the collective share of regional tissue engineered skin substitute providers is quite large, the reach of key players coupled with the strict set of guidelines governing the release of any product in the market, have created only a moderate threat level from new entrants.

This 67 page report gives readers a comprehensive overview of the tissue engineered skin substitutes market. Browse to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/tissue-engineered-skin-substitute.html

The global market for tissue engineered skin substitutes is expected to generate revenue at a highly positive CAGR of 17.2% within a forecast period from 2015 to 2023. This market is expected to generate a revenue of US$1.2 bn by the end of 2016, and US$3.87 bn by 2023.

Medical Tourism Creates Wide Revenue Stream for Tissue Engineered Skin Substitute Providers

“Medical tourism, as an industry, is already a multi-billion dollar one and is showing an annual growth rate in double digits,” states a TMR analyst. “The use of tissue engineered skin substitutes in developed nations is not only growing in numbers, but is also over-expensive and unaffordable for some without a feasible reimbursement policy. As a result, a large number of patients seeking tissue engineered skin substitute treatment are doing so through medical tourism.”

Nations such as Thailand, Malaysia, India, and Singapore are at the forefront of medical tourism and can offer state of the art technologies for tissue engineered skin substitute treatment at a much cheaper rate than that from North America or Europe.

Additionally, medspas, or medical clinics that include a day spa, are a highly preferred place for treatment and healing by the elderly, especially for cases such as treatment of ulcers and venous diseases. Their higher number in developing economies is another factor driving the scope of medical tourism in the tissue engineered skin substitute market.

Cost Effectiveness of Tissue Engineered Skin Substitutes Reduced by Intense Competition

The presence of a large number of local players adds a major layer of restraint to the globally prominent ones for the tissue engineered skin substitutes market. Local players can offer products at a much cheaper cost, thereby forcing key players to match their prices and reduce profit margins.

Request a sample of this report to know what opportunities will emerge in the rapidly evolving tissue engineered skin substitutes market during 2015 - 2023: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3854

The profits that can be channeled into research and development, therefore, decrease, slowing down the overall growth of the market for tissue engineered skin substitutes. This is more prevalent in developing economies, where the disparity in costs between local and global tissue engineered skin substitute players is quite high.

Asia Pacific to Scale up Demand for Tissue Engineered Skin Substitutes

Owing to a growing population and a rapidly improving healthcare infrastructure in terms of quality and outreach, Asia Pacific is expected to show the fastest growth rate for tissue engineered skin substitutes. It is expected to progress at a CAGR of 18.3% within the forecast period from 2015 to 2023.

Acellular skin substitutes have not only been the dominant type of tissue engineered skin substitutes, but have registered promising growth. From 2015 to 2023, this segment is expected to progress at a CAGR of 17.8%. The leading application for tissue engineered skin substitutes is to treat ulcers. This application segment is expected to progress at a CAGR of 17.5% from 2015 to 2023.

The information presented in this review is based on a Transparency Market Research report, titled, “Tissue Engineered Skin Substitutes Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023.”

Thyroid Gland Disorders Treatment Market: Impact of Key Factors Influencing the Parent Industry

AbbVie, Inc., Merck KGaA, Abbott Laboratories, and Pfizer, Inc., were the leading providers of thyroid gland disorder drugs in the world in 2014. Their collective market share of 69.3% in 2014 points to a highly consolidated market. According to a new research report released by Transparency Market Research, most key manufacturers of thyroid gland disorder treatments are highly attracted towards Asia Pacific. This region promises players a high growth rate due to the high population densities and rapidly developing healthcare sector.

TMR also discusses the impact of key events on the overall sales of thyroid gland disorder drugs. This includes the voluntary recall for Levoxyl made by Pfizer, Inc., in 2013, and the latest decisions and movements that occurred in the 2015 International Thyroid Congress.

This 104 page report gives readers a comprehensive overview of the

thyroid gland disorders treatment market. Browse to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/thyroid-gland-disorder-market.html

Growing Thyroid Disorder Patient Numbers Push Treatment Development Speeds

“The WHO and other related organizations such as the AACE have all stated that the number of people suffering from thyroid gland disorders is increasing at a rapid rate,” states a TMR analyst. “This is a direct driver for the players in the thyroid gland disorders market as they are being encouraged to intensify their developments on new and effective drugs and treatments.

Additionally, the count of patients with thyroid gland disorders is expected to increase due to the growing number of patients with issues such as CVD, diabetes, and obesity. These illnesses significantly increase the chances of a person suffering from thyroid gland disorders, thereby increasing the consumption of relevant drugs.

Rise in Alternative Treatments Hindering Thyroid Gland Disorders Treatment Development

Patients are not satisfied with the current thyroid gland disorders drugs that are commercially available. The artificially created drugs are not completely effective in balancing the level of thyroid in the body. Achieving balance requires the help of alternative medical practices that are also considered as safer.

Patients suffering from thyroid gland disorders are increasingly shifting focus from conventional market drugs to alternative medical practices. This includes the consumption of special herbal medicines from China or the use of acupuncture.

Asia Pacific Increases Thyroid Gland Disorders Treatment Demand, North America Continues to Lead it

The global thyroid gland disorder market is expected to expand at a CAGR of 3.1% within a forecast period from 2015 to 2023 in terms of revenue. This market is expected to be valued close to US$1.99 bn by the end of 2016. By 2023, this revenue is expected to reach US$2.41 bn.

Request a sample of this report to know what opportunities will emerge in the rapidly evolving thyroid gland disorders Treatment market during 2015 - 2023: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3113

The key region responsible for the growth in demand for thyroid gland disorder treatment is North America. By the end of 2023, the revenue earned by thyroid gland disorder treatment providers is expected to reach US$1.1 bn. This is attributed to the increasing counts of patients with hyperthyroidism and hypothyroidism. The development of thyroid gland disorder drugs in North America has also sped up due to the increasing expenditure in the region’s healthcare industry. From a global perspective, the treatment solutions for hypothyroidism are showing the faster CAGR of 3.2% from 2015 to 2023.

In terms of drug segments, levothyroxine is displaying the fastest CAGR of 3.4% from 2015 to 2023 for hypothyroidism. Imidazole is the most consumed drug for the treatment of hyperthyroidism. It is expected to progress at a CAGR of 2.4% from 2015 to 2023.

The information presented in this review is based on a Transparency Market Research report, titled, “Thyroid Gland Disorders Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023.”

Key Takeaways:

• The market for hypothyroidism drugs is expected to reach US$2.05 bn by 2023.
• Levothyroxine to remain the most popular hypothyroidism drug, expected to earn a revenue of US$2.04 bn by 2023.
• Imidazole to remain the most popular hyperthyroidism drug, expected to earn a revenue of US$349 mn by 2023.

Antibacterial Drugs Market: Business Challenges, Emerging Technologies & Competitive Landscape

A new market research study, titled “Antibacterial Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023,” has been published by Transparency Market Research. As per the study, in 2014, the global antibacterial drugs market was worth US$43.9 bn. The market is projected to exhibit a 1.30% CAGR between 2015 and 2023, declining in value to touch US$38.9 bn by the end of 2023.

An antibacterial drug is an antimicrobial agent that interferes with the reproduction and growth of bacteria. The growth of this bacteria can cause severe infections in animals and humans. The administration of antibacterial drugs helps in inhibiting the growth of the bacteria or completely killing it. At present, several antibacterial drugs in different formulations are available and are widely used for treating tuberculosis, legionellosis, like pneumonia, diarrhea, diphtheria, tetanus, and other diseases. Some of the prominent consumers of the global antibacterial drugs market are private clinics, hospitals, patients, and physicians.

This 110 page report gives readers a comprehensive overview of the antibacterial drugs market. Browse through 9 data tables and 40 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/antibacterial-drugs-market.html

The growing prevalence of infections and other diseases across the globe and increasing government support for research and development activities are some of the key drivers of the global antibacterial drugs market. However, the upcoming patent expirations and growth in drug-resistant species are projected to curtail the growth of the market in the coming years. The decline in the markets valuations will primarily be attributable to this negative factor.

In 2014, the β-lactams segment accounted for a 58% share in the global antibacterial drugs market and is estimated to be in the topmost position in the next few years. In the same year, the quinolones segment accounted for a 17% share in the global market and is expected to exhibit negative growth rate in the forecast period. Furthermore, the miscellaneous antibacterial segment is projected to witness significant growth owing to the growing demand for therapies against bacterial infections and rising geriatric population.

The strong pipeline in the global antibacterial drugs market includes RHB-105, Eravacycline, Ozenoxacin, Arikace, Carbavance (meropenem/RPX7009), Surotomycin (MK-4261), SYM-1219, Solithromycin (CEM-101), Plazomycin, Ciprofloxacin/Fluocinolone Acetonide, SPL7013, Actoxumab/Aezlotoxumab, (MK-3415A), Omadacycline (PTK-0796), Zempia (E-101), Cadazolid, Delafloxacin, and Delamanid. The major players are making constant efforts to commercialize these drugs, which is estimated to propel the global antibacterial drugs market in the near future.

At present, Asia Pacific accounts for the largest share in the global antibacterial drugs market and is projected to grow at a fast pace throughout the forecast period. The rapid growth of this region can be attributed to the strong presence of generic pharmaceutical ingredients and generic manufacturers, a growing geriatric population, and expanding population. In addition, the growing incidence of several bacterial infections including MRSA and TB, developing healthcare infrastructure, and rising purchasing power of consumers are some of the other factors anticipated to drive global antibacterial drugs market in the coming years.

Request a sample of this report to know what opportunities will emerge in the rapidly evolving antibacterial drugs market during 2015 - 2023: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1567

Asia Pacific is followed by North America and Europe. These regions are expected to witness sluggish growth throughout the forecast period. The slow-paced growth of the North America and Europe antibacterial drugs markets can be attributed to the strict regulatory requirements, market maturity, and shortened product lifecycle.

The prominent players engaged in the global antibacterial drugs market include Bayer AG, Forest Laboratories, Inc., Allergan plc, Johnson & Johnson, AstraZeneca plc, Sanofi, GlaxoSmithKline plc, Bristol-Myers Squibb Company, Eli Lilly & Co., Novartis AG, Merck & Co., Inc., and Pfizer, Inc. These players are leading the overall market and witnessing intense competition amongst each other. Among these players, Pfizer, Inc. is considered as a dominant player owing to its significant contribution towards the global antibacterial drugs market.

Organ Transplant Immunosuppressant Drugs Market: Worldwide Market Shares, Strategies, and Forecasts 2015 to 2023

The global organ transplant immunosuppressant drugs market exhibits a highly consolidated vendor landscape. The top five companies held more than 90% of the market in 2014. These companies boast a strong and diverse product portfolio that has helped them attain a leading position in the market. Transparency Market Research (TMR) finds that in order to gain a stronger footprint, the leading companies are continuously engaged in the research and development of novel therapeutics.

“Despite the impending patient expiry of blockbuster drugs, the leading companies are looking to update their pipelines to ensure sustainable growth in the market,” said a lead TMR analyst. Besides this, the companies are also focusing on collaborations and mergers and acquisitions to strengthen their value chain.

This 102 page report gives readers a comprehensive overview of the organ transplant immunosuppressant drugs market. Browse to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/organ-transplant-immunosuppressant-drugs.html

Rising Organ Replacement Therapies Boosts Sales of Immunosuppressant Drugs

The increasing incidence of life-threatening diseases has augmented the demand for organ replacements and transplants as last resorts of treatment in case of organ failure or disabilities. Due to this, the number of people registering for organ transplantation has significantly increased as well. The increase in geriatric population directly influences the demand for organ transplants since aged people are more vulnerable to kidney and heart diseases. The rising incidence of chronic ailments will therefore fuel demand for organ transplant immunosuppressant drugs.

High Cost of Organ Replacement Surgeries Poses Threat to Market

“Despite witnessing increasing demand, the high cost of organ transplant procedures limits the scope for the market’s expansion,” observed the TMR analyst. Non-adherence of patients to immunosuppressive medicines across developing regions is often related to their high cost and the patient’s inability to pay for the same. Furthermore, the high cost of post-transplantation care presents a significant barrier to the development of transplantation capacity in middle-income countries. The inadequate insurance coverage also limits the sales of organ transplant immunosuppressant drugs in these countries.

The development of immunosuppressant drugs help overcome conditions related to organ rejection. Significant advances have been made in the field of medicine and technology, yet a large section of global population is yet become aware about organ transplantation and donation. This has created a considerable shortage of donor organs, thus negatively impacting the sales of immunosuppressant drugs.

Besides this, the advent of stem cell therapies could eventually reduce the need for organ transplants. This also threatens the growth prospects of the organ transplant immunosuppressant drugs market.

Nevertheless, extensive studies are underway to develop and test novel immunosuppressant therapeutics to prevent organ rejection. Such research and development activities will create opportunities for the market to gain from in the forthcoming years.

Request a sample of this report to know what opportunities will emerge in the rapidly evolving organ transplant immunosuppressant drugs market during 2015 - 2023: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1967

According to TMR, the global organ transplant immunosuppressant drugs market stood at US$5.1 bn in 2014. Rising at a CAGR of -5.0%, the market is expected to reach US$3.2 bn by the end of 2023.

Based on the type of transplantation performed across the world each year, the demand for immunosuppressant drugs used in kidney transplantation was the highest in 2014. The segment held over 53.4% of the market’s revenue in the year. Regionally, North America dominated the global market with a share of 46.2% in 2014. The region is expected to continue to be a key contributor to the market through the report’s forecast period from 2015 to 2023.

This review is based on findings published by TMR, in a report, titled “Organ Transplant Immunosuppressant Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023.”

Key Takeaways:

• Inadequate insurance coverage to limit sales of immunosuppressant drugs in developing countries.
• North America dominated the global immunosuppressant drugs market in 2014 with a share of 46.2%.
• Advent of stem cell therapy will contribute to declining CAGR of the market at -5.0% from 2014 to 2023.

Multi-parameter Patient Monitoring Equipment Market: Business Challenges, Emerging Technologies & Competitive Landscape

Close to 71% of the total value of global multi-parameter patient monitoring equipment market in 2014 was taken up by the top three players – Philips Healthcare, GE Healthcare, and Drägwerk AG & Co. KGaA. Product innovation is a key strategy adopted by them and other prominent players in this primarily oligopolistic market.

According to a new publication by Transparency Market Research, the threat of new entrants in the multi-parameter patient monitoring equipment market is expected to remain moderate. While the demand for the equipment is increasing, extremely strict guidelines and high initial costs of the monitors prevail, deterring many new entrants from gaining ground in the market.

Meanwhile, the degree of competition in the market is expected to remain high over the coming years as prominent players keep looking for ways to increase market share.

This 91 page report gives readers a comprehensive overview of the multi-parameter patient monitoring equipment market. Browse through 9 data tables and 30 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/multi-parameter-patient-monitoring-equipment.html

The revenue generated in the global market for multi-parameter patient monitoring equipment is expected to progress at a CAGR of 4.4% within a forecast period from 2015 to 2023. The revenue is expected to reach US$4.65 mn by the end of 2023 and US$3.47 bn by the end of 2016.

North America has enjoyed being a high development and high demand region for multi-parameter patient monitoring equipment. By the end of 2023, this region’s revenue in the market is expected to reach US$2.39 bn. Meanwhile, the demand for multi-parameter patient monitoring equipment grows faster in the Asia Pacific region.

High-Acuity Monitors Comprise Major Demand

A large part of the demand for multi-parameter patient monitoring equipment is currently for high-acuity monitors. These monitors are expected to generate a revenue progressing at a CAGR of 5.2% from 2015 to 2023 and is expected to reach close to US$2 bn.

The demand for multi-parameter patient monitoring equipment is growing at a significant pace in the home healthcare segment till 2023. Despite that, the sheer volume of demand for multi-parameter patient monitoring equipment in hospitals is expected to continue leading the market value, reaching US$3.45 bn by 2023.

Mid- and Low-acuity Patient Monitoring Equipment to Gain Demand through Remote Monitoring Healthcare Boom

“One of the greater shifts in the market for multi-parameter patient monitoring equipment that manufacturers need to look out for is the growth in demand for mid- and low-acuity patient monitoring equipment in the coming years,” states a TMR analyst. “Home healthcare services are witnessing an enormous demand and it will continue to increase over the coming years, owing to a growing geriatric population and the advancement of remote monitoring healthcare services,” the analyst adds.

Home healthcare services offer significant advantages such as reducing overall expenses and the number of hospital visits for patients and are therefore in extremely high demand. These are also the same patients that are fall into the brackets of mid- and low-acuity issues.

High Product Recall Rate Disturbs Natural Growth of Multi-parameter Patient Monitoring Equipment Market

There have been multiple recalls of several types of multi-parameter patient monitoring equipment over the recent past owing to several reasons. A key reason for product recalls was the misinterpretation of sensory data to give the wrong reading, thereby leading doctors to make false conclusions.

Request a sample of this report to know what opportunities will emerge in the rapidly evolving multi-parameter patient monitoring equipment market during 2015 - 2023: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1692

It is not just medium and small scale manufacturers that have had to issues recalls; several globally prominent entities have also been subject to consumer grievances and large scale product recalls.

The future of multi-parameter patient monitoring equipment could very well lie in emerging economies, as mentioned by the TMR analyst: “Major opportunities lie in the developing regions for the implementation multi-parameter patient monitoring equipment. Nations in Asia Pacific, for instance, are showing a high rate of healthcare evolution and will surely give wide berth to manufacturers of advanced medical equipment.”

The information presented in this review is based on a Transparency Market Research report, titled, “Multi-parameter Patient Monitoring Equipment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023.”

Key Takeaways:

• High-acuity monitors expected to lead the global multi-parameter patient monitoring equipment market till 2023, expected to reach US$2.00 bn by then.
• Hospital demand for multi-parameter patient monitoring equipment dominates till 2023, expected to reach US$3.45 bn by then.
• North America continues taking up majority revenue in multi-parameter patient monitoring equipment, expected to generate US$2.39 bn by 2023.